GlobeNewswire Inc | May 26, 2021 04:18PM EDT

May 26, 2021

BOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government andmilitary use, today announced that the Company will present at the Jefferies Virtual Healthcare Conference which will be broadcast on Wednesday, June 2, 2021 at 9:00 a.m. ET.

To access the live webcast of Paratek's presentation, please visit https://wsw.com/webcast/jeff174/prtk/1878903.

Please connect to the web site at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast can be accessed for up to 90 days following the live presentation.

About Paratek Pharmaceuticals, Inc.Paratek Pharmaceuticals, Inc.is a commercial-stage biopharmaceutical companyfocused on the development and commercialization of novel life-saving therapiesfor life-threatening diseases or other public health threats for civilian,government andmilitary use.

The Company?s lead commercial product, NUZYRA(omadacycline), isa once-dailyoral and intravenous antibiotic available in the U.S. for the treatment ofadults with community-acquired bacterial pneumonia and acute bacterial skin andskin structure infections. Paratek has a collaboration agreement withZaiLabfor the development and commercialization of omadacycline in thegreaterChinaregion and retains all remaining global rights.

Paratek exclusively licensed U.S. rights and rights to the greater Chinaterritory for SEYSARA (sarecycline), a once-daily oral therapy for thetreatment of moderate to severe acne vulgaris, toAlmirall, LLC(Almirall).Paratek retains the development and commercialization rights for sarecycline inthe rest of the world.

In 2019, Paratek was awarded a contract from BARDA, valued at ~$285 million,tosupport the development and U.S.-based manufacturing of NUZYRA for thetreatment of pulmonary anthrax.

For more information, visitwww.ParatekPharma.comor follow @ParatekPharmaonTwitter.

Forward Looking StatementsThis press release contains forward-looking statements including statementsrelated to our overall strategy, products, prospects and potential.Allstatements, other than statements of historical facts, included in this pressrelease are forward-looking statements, and are identified by words such as"advancing," "expect," "look forward," "anticipate," "continue," and otherwords and terms of similar meaning. These forward-looking statements are basedupon our current expectations and involve substantial risks and uncertainties.We may not actually achieve the plans, carry out the intentions or meet theexpectations or projections disclosed in our forward-looking statements and youshould not place undue reliance on these forward-looking statements. Ouractual results and the timing of events could differ materially from thoseincluded in such forward-looking statements as a result of these risks anduncertainties. These and other risk factors are discussed under "Risk Factors"and elsewhere in our Annual Report on Form 10-K forthe year ended December 31,2020 and our other filings with the Securities and Exchange Commission. Weexpressly disclaim any obligation or undertaking to update or revise anyforward-looking statements contained herein.

CONTACT:

Investor and Media Relations: Ben Strain 617-807-6688 ir@ParatekPharma.com